Preclinical pharmacological studies of antitumor and other therapeutic agents

Ended Definitive Contract Awarded Last action

Contract number
HHSN261200522001C
Awardee
Awarding agency
Obligated
$4,288,592

Award facts

Opportunity
  • N01CM4701545 Solicitation number
Contract value 20% obligated
  • $12,648,534.02 Current, with exercised options
  • $21,593,775.02 Potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
Not on record
Set-aside
No set-aside
Competition
Full and Open Competition · 9 offers Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Menlo Park, CA 94025, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Close Out 17 · This modification deobligates uninvoiced funds that remained at contract closeout. -$189,027
Other Administrative Action 16 · This modification deobligates uninvoiced arra funds and expiring FY 2008 funds. -$41,859
Other Administrative Action 15 · Other functions this modification revises sections g and h of the contract to reflect hhsar updates and additional OFM invoicing instructions. $0
Funding Only Action 14 · Deobligating expiring funds. -$2,099
Funding Only Action 13 $57,300
Exercise an Option 12 $0
Supplemental Agreement for work within scope 11 · Arra::yes::arra recovery act "in vitro screening of combinations of drugs to treat cancer" $3,100,000
Exercise an Option 10 $70,000
Funding Only Action 9 $93,514
Supplemental Agreement for work within scope 8 $170,000
Other Administrative Action 7 $0
Funding Only Action 6 $190,000
Other Administrative Action 5 $0
Funding Only Action 4 $174,796
Funding Only Action 3 $170,000
Funding Only Action 2 $168,994
Funding Only Action 1 $163,486
Original award $163,487
Show all 18

About this award

Written by GovTribe AI ·

This is a federal contract award from the National Cancer Institute, a civilian agency within the Department of Health and Human Services, to SRI International, a non-profit research and development institute. The contract, worth $21,593,775.02, is for "PRECLINICAL PHARMACOLOGICAL STUDIES OF ANTITUMOR AND OTHER THERAPEUTIC AGENTS" and was awarded on December 15, 2004 with a completion date of December 14, 2012. The contract type is Definitive Contract with a Cost Plus Fixed Fee pricing structure. This contract does not have a set-aside designation. SRI International is a large non-profit organization that frequently partners with federal agencies, including the Department of Defense, NASA, and the Department of Education, to provide scientific, engineering, and technical services through contracts and grants. The National Cancer Institute utilizes multiple indefinite delivery vehicles (IDVs) with SRI International to efficiently access their biomedical research capabilities, including drug development services.

Quick answers

Who was awarded contract HHSN261200522001C?

HHSN261200522001C was awarded to Sri International by National Cancer Institute (National Institutes of Health) on December 15, 2004.

How much is contract HHSN261200522001C worth?

The government has obligated $4,288,592 on HHSN261200522001C. Its current value, with exercised options, is $12,648,534. Its potential value, with all options, is $21,593,775.

Was contract HHSN261200522001C competed?

The extent of competition for HHSN261200522001C was full and open competition. The government received 9 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login